Details of the Drug-Related molecule(s) Interaction Atlas

Benzoxazinone derivative 2 Drug Info

PMID29171765-Compound-Figure3

Cross-matching ID

TTD Drug ID

DM4FHTG

General Information of Drug (ID: DM4FHTG)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Kallikrein-related peptidase (KLK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bortezomib	DMNO38U	Leukemia		Approved	[2]
Ecallantide	DMOF2C6	Retina venous occlusion	9B74.1	Approved	[3]
Cetraxate	DMSP4JX	Peptic ulcer	DA61	Approved	[4]
LM-030	DMSJOE3	Congenital ichthyosiform erythroderma	EC20.02	Phase 2	[5]
Benzyl amine derivative 1	DMOU84B	N. A.	N. A.	Patented	[1]
Benzyl amine derivative 2	DMFK7EL	N. A.	N. A.	Patented	[1]
Heteroaryl-carboxamide derivative 11	DM1CWU7	N. A.	N. A.	Patented	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Kallikrein-4 (KLK4)	TT4319X	KLK4_HUMAN	Inhibitor	[1]
Kallikrein-related peptidase (KLK)	TT5L2VC	NOUNIPROTAC	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Serine protease inhibitors to treat inflammation: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Feb;28(2):93-110.
2	Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. J Med Chem. 1995 Apr 28;38(9):1511-22.
3	Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther. 2008 Aug;8(8):1187-99.
4	A new broad spectrum inhibitor of esteroproteases, 4-(2-carboxyethyl) phenyl-trans-4-aminomethyl cyclohexane carboxylate hydrochloride (DV 1006). Tohoku J Exp Med. 1972 Mar;106(3):233-48.
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)